On 16^th, October 2024, Hasten Biopharmaceutical Co., Ltd. (hereinafter as Hasten) announced that a new network META article of azilsartan medoxomil (AZL-M) titled "A systematic literature review and network meta-analysis of azilsartan medoxomil compared to other anti-hypertensives efficacy in lowering blood pressure amongst mild to moderate hypertensive patients" had been published in the internationally renowned journal Advances in Therapy.

According to the conclusion of this network META, AZL-M at 40mg and 80mg shows favorable efficacy compared to other anti-hypertensives, and the 80mg dosage seemed to be most efficacious of all the included treatments in reducing both office systolic and diastolic BP in patients with mild to moderate hypertension. 

The publication of the results of this META indicates the international peer-review’s recognition of the quality of this data analyzed.

Prof. Shen XIAO, Chief Medical Officer of Hasten, stated that as a meta-analysis covering professional literature from the past 24 years, the META provides an adequate data support for assessing the efficacy of azilsartan medoxomil compared to other commonly used first-line antihypertensive drugs. The results of this network META indicate that azilsartan medoxomil, as an effective antihypertensive treatment for patients with mild to moderate hypertension, will offer a new and more effective option for the treatment of a greater number of hypertensive patients.

Reference：

Qian JY. A systematic literature review and network meta-analysis of azilsartan medoxomil compared to other anti-hypertensives efficacy in lowering blood pressure amongst mild to moderate hypertensive patients (http://doi.org/10.1007/s12325-024-02997-5).